Get the Stockscreener App
0.308
1.03%
-0.0032
After Hours:
.32
0.012
+3.90%
Scisparc Ltd stock is traded at $0.308, with a volume of 242.49K.
It is down -1.03% in the last 24 hours and down -17.43% over the past month.
See More
Previous Close:
$0.3112
Open:
$0.314
24h Volume:
242.49K
Relative Volume:
0.03
Market Cap:
$3.51M
Revenue:
$1.75M
Net Income/Loss:
$-5.68M
P/E Ratio:
-0.0632
EPS:
-4.8726
Net Cash Flow:
-
1W Performance:
-5.52%
1M Performance:
-17.43%
6M Performance:
+23.20%
1Y Performance:
-82.60%
1-Day Range:
$0.3011
$0.3255
1-Week Range:
$0.30
$0.3421
52-Week Range:
$0.197
$2.10
Scisparc Ltd Stock (SPRC) Company Profile
Compare SPRC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
0.308 | 3.51M | 1.75M | -5.68M | 0 | -4.8726 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 36.26B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.91B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Scisparc Ltd Stock (SPRC) Latest News
SciSparc Ltd. (NASDAQ:SPRC) Short Interest Up 1,435.0% in March - Defense World
SciSparc announces resale of 61.21M shares by selling shareholders; shares down - MSN
SciSparc and Clearmind Advance Cocaine Addiction Treatment with South Korean Patent Application - TipRanks
Is the SciSparc Ltd (NASDAQ:SPRC) stock an investment opportunity? - US Post News
SciSparc-Clearmind Collaboration Leads to Publication of - GlobeNewswire
SciSparc Shares Are Soaring Monday: What's Going On? - Benzinga India
Scisparc, Clearmind apply for patent in South Korea for its co-developed treatment to overcome cocaine addiction - Marketscreener.com
SciSparc announces publication of patent via Clearmind collaboration - TipRanks
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea - The Manila Times
SciSparc Ltd. and Clearmind Medicine Inc. Announce Patent Application for Combination Treatment of Cocaine Addiction - Nasdaq
SciSparc Advances Cocaine Treatment Patent Following Successful Preclinical Data - StockTitan
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea - The Manila Times
SciSparc Extends $2 Million Loan to Support Automax?s Growth Following Automax?s Entry into Direct Import of JAC Electric Vehicles - Marketscreener.com
SciSparc Ltd. Agrees to Sell MitoCareX to N2OFF - TipRanks
SciSparc signs definitive agreement to sell MitoCareX to N2OFF - TipRanks
SciSparc to sell MitoCareX to N2Off for $700,000 - MSN
SciSparc divests MitoCareX stake for $700,000 and stock swa By Investing.com - Investing.com South Africa
SciSparc divests MitoCareX stake for $700,000 and stock swa - Investing.com
SciSparc Ltd. Announces Sale of MitoCareX Shares to N2Off for $700,000 and Stock Exchange Agreement - Nasdaq
SciSparc Signs Definitive Agreement to Sell MitoCareX, - GlobeNewswire
SciSparc's Strategic Exit: How Its MitoCareX Sale Could Deliver $2.3M+ in Value - StockTitan
SciSparc Ltd. announced that it expects to receive $2 million in funding from Yorkville Advisors Global LP - Marketscreener.com
SciSparc Extends $2 Million Loan to Support AutoMax's - GlobeNewswire
SciSparc provides $2 million loan to AutoMax for expansion - Investing.com Australia
SciSparc Enters $4.2M Securities Agreement and Supports AutoMax Expansion with $2M Loan - TipRanks
SciSparc provides $2 million loan to AutoMax for expansion By Investing.com - Investing.com South Africa
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles - The Manila Times
SciSparc extends $2M loan to support AutoMax growth - TipRanks
SciSparc Ltd. Enters $2 Million Loan Agreement with AutoMax Motors to Support Business Expansion - Nasdaq
SciSparc Bets $2M on Electric Vehicle Future with Latest AutoMax Financing - StockTitan
N2OFF to acquire biotech firm MitoCareX in strategic move - Investing.com
SciSparc Ltd. Reaches Favorable Lawsuit Settlement, Secures Cash Compensation and IP Rights - TipRanks
How Are Things Looking For SciSparc Ltd (NASDAQ: SPRC) For The Short Term? - Stocks Register
SciSparc Reveals Favorable Cash Settlement In Lawsuit, Shares Up - Nasdaq
SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology - The Manila Times
SciSparc Ltd. Secures Settlement Agreement in Lawsuit Against Former Directors, Retaining Key Intellectual Property Rights - Nasdaq
SciSparc Secures Favorable Settlement in Lawsuit It Filed, - GlobeNewswire
Legal Victory: SciSparc Claims $411K Settlement and Complete IP Control in Strategic Court Win - StockTitan
Investor Ideas New Stocks to Watch in Life Sciences and AI - Investorideas.com newswire
SPRC’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
SciSparc Ltd (SPRC) Shares Soar Above 1-Year High - The News Heater
Views of Wall Street’s Leading Experts on SciSparc Ltd - SETE News
Behind SciSparc Ltd’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - GlobeNewswire
SciSparc and Clearmind’s Patent Publication Marks Progress in Binge Behavior Treatment - TipRanks
SciSparc Ltd.-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - Marketscreener.com
SciSparc Ltd. and Clearmind Medicine Inc. Collaborate on Patent Application for Innovative Combination Therapy to Address Binge Behaviors - Nasdaq
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico - The Manila Times
SciSparc gets U.S. FDA nod to begin phase 2 trial of Tourette Syndrome candidate - MSN
Jeffs' Brands Negotiates $11.8M Sale of Smart Repair Pro to Canadian Company in Major Restructuring - StockTitan
Minerva Neurosciences (NASDAQ:NERV) vs. SciSparc (NASDAQ:SPRC) Financial Contrast - Defense World
Scisparc Ltd Stock (SPRC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.39%
0.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):